CD Biosynsis offers state-of-the-art HeLa Cells Base Editing Services, providing precise, single-nucleotide substitution without generating a DNA double-strand break (DSB). This advanced technology is ideal for highly controlled engineering of this foundational human cancer cell line. Base Editing (BE) is essential for applications requiring subtle genetic tuning in HeLa cells, such as optimizing promoter activities, introducing specific point mutations (SNPs) to mimic cancer-related variants, or creating clean functional knockouts via stop codon insertion. By employing a fused dCas9 or nickase Cas9 (nCas9) with a specific deaminase, Base Editing converts one target base pair to another (e.g., C:G to T:A or A:T to G:C) with unparalleled efficiency and minimal byproducts. This platform is key to achieving precise, subtle genomic control, accelerating the study of cancer mechanisms and drug target validation.
Get a QuoteTraditional CRISPR-Cas9 for point mutations relies on the low-efficiency HDR pathway and risks generating unwanted indels via NHEJ. Base Editing overcomes these limitations by performing the nucleotide conversion directly. This involves a complex fusion protein—typically a dCas9 or nCas9 (which nicks only one strand) linked to a specific deaminase. The deaminase chemically converts the target base within the editing window specified by the gRNA. This DSB-free mechanism ensures high efficiency, low off-target effects, and minimal indel formation, making it the premier choice for subtle, tunable genomic control and creating high-fidelity isogenic models in complex HeLa cells.
Cytidine Base Editors (CBE)
Fuses nCas9/dCas9 with a cytidine deaminase, facilitating the conversion of C:G base pairs to T:A base pairs (C>T conversion) within a defined editing window.
Adenosine Base Editors (ABE)
Fuses nCas9/dCas9 with an adenosine deaminase, enabling the conversion of A:T base pairs to G:C base pairs (A>G conversion), expanding the base editing scope.
Optimized Delivery Systems
Use of specialized, high-fidelity Base Editor variants (e.g., different Cas9 domains or optimized deaminases) delivered via plasmid or RNP to maximize on-target purity.
Point Mutation Modeling (SNPs)
Precise introduction of single-nucleotide polymorphisms (SNPs) or missense mutations into coding sequences to study the functional impact of cancer-related variants.
Stop Codon Insertion
Targeting specific codons to introduce premature stop codons (PTC) for highly efficient, clean gene disruption, an alternative to Cas9 KO via NHEJ.
Regulatory Element Tuning
Editing bases in promoter, enhancer, or UTR sequences to subtly adjust gene expression levels, helping to map the contribution of non-coding elements to cell function.
Isogenic Cancer Modeling
Precise introduction or correction of oncogenic mutations into control cell lines to create isogenic pairs for drug screening and mechanistic studies.
Viral Host Factor Tuning
Tuning the expression of host factors involved in viral entry or replication by editing their promoter regions, assessing the dose-dependent effect on infection.
Drug Resistance Mechanism
Introducing mutations found in resistant cancer clones to validate their role in reducing drug efficacy or promoting cell survival.
A precision-guided process for single-nucleotide substitution and clonal verification.
1. Target Design & Editor Selection
2. Editor Delivery & Editing
3. Single Cell Cloning & Screening
4. Verification & Stable Clone Delivery
Identify the target base pair and the desired substitution (e.g., C>T or A>G). Select the optimal Base Editor (CBE or ABE) variant.
Design gRNA(s) to place the target base within the optimal editing window for high conversion efficiency and allelic coverage in HeLa cells.
Define screening assays (sequencing, functional assay) to detect the desired point mutation.
Deliver the Base Editor (plasmid or RNP) and the optimized gRNA into the HeLa host line (Build) via optimized protocols (electroporation/lipofection).
Culture cells for transient expression to allow the deaminase to perform the base conversion.
Apply selection markers or FACS sorting to enrich for high-editing populations.
Genotype verification via Sanger or Deep Sequencing across the edited window to confirm the base change, multi-allelic status, purity, and low indel rate (Learn).
Phenotypic validation of the resulting functional trait (e.g., altered protein function, changed gene expression).
Delivery of the verified research clone and comprehensive documentation.
DSB-Free Precision
Elimination of the DNA double-strand break (DSB) ensures minimal indel formation, low toxicity, and clean, highly efficient base conversion in the complex HeLa genome.
High Efficiency SNP Modeling
Base editing is significantly more efficient than HDR for single-point mutations, drastically accelerating the creation of high-fidelity isogenic cancer models.
Clean Gene Disruption
Allows for highly specific, clean functional knockouts by introducing premature stop codons, providing an alternative to traditional NHEJ-based KO.
Aneuploidy Management
High editing frequency enables screening for clones where the desired base substitution is present across all functional alleles, overcoming the challenge of high ploidy.
1. What types of base pair conversions can Base Editing achieve?
We primarily offer Cytidine Base Editors (CBEs) for C:G to T:A conversion (C>T) and Adenosine Base Editors (ABEs) for A:T to G:C conversion (A>G).
2. Why is Base Editing preferred over CRISPR/HDR for single-point mutations?
Base Editing does not create a double-strand break, resulting in much higher efficiency (less reliance on HDR pathway) and a significantly lower risk of unwanted insertions and deletions (indels).
3. How is Base Editing used to model cancer in HeLa cells?
We use BE to precisely introduce or correct specific single nucleotide polymorphisms (SNPs) known to drive oncogenesis or drug resistance (e.g., in KRAS or EGFR), creating clean, isogenic research controls.
4. How do you verify multi-allelic base editing in aneuploid HeLa cells?
Due to the high ploidy, we rely on deep sequencing of the edited locus to quantify the percentage of functional alleles that have achieved the desired base change, followed by functional screening of monoclonal clones.
5. What is the "editing window" for gRNA design in BE?
The editing window is the specific range of bases (typically positions 3-7 or 4-8) within the gRNA target sequence where the deaminase is active. The target base must be precisely positioned for successful conversion.
6. What input is required to start a Base Editing project?
We require the specific HeLa cell line, the target gene sequence (accession number or sequence), and the precise base pair change you wish to introduce (e.g., G > A at position X).
7. Can Base Editing be used to mimic drug resistance?
Yes. Introducing known point mutations responsible for drug resistance into a drug-sensitive HeLa line allows researchers to definitively study the mechanism by which the SNP confers resistance.
8. How is a clean functional knockout achieved using Base Editing?
We target a codon within the gene to convert it into a premature stop codon (PTC). This truncates the resulting protein, cleanly eliminating function without the complex mix of indels typical of NHEJ-based Cas9 knockout.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.